0001209191-24-000816.txt : 20240104
0001209191-24-000816.hdr.sgml : 20240104
20240104164546
ACCESSION NUMBER: 0001209191-24-000816
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pizzuti Dana
CENTRAL INDEX KEY: 0001948238
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 24512785
MAIL ADDRESS:
STREET 1: C/O CRINETICS PHARMACEUTICALS, INC.
STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-03
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001948238
Pizzuti Dana
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
0
1
0
0
Chief Med and Dev Officer
1
Common Stock
2024-01-03
4
M
0
14375
16.89
A
20286
D
Common Stock
2024-01-03
4
S
0
14375
35.00
D
5911
D
Non-qualified stock option (Right to Buy)
16.89
2024-01-03
4
M
0
14375
0.00
D
2032-10-10
Common Stock
14375
206042
D
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.00 per share. The range of sales prices on the transaction date was $34.82 to $35.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Marc Wilson
2024-01-04